#United States #San Diego #Class Action #Robbins LLP #Neumora Therapeutics

Investor Alert on Neumora Therapeutics

Robbins LLP has announced that a class action lawsuit has been initiated for shareholders of Neumora Therapeutics, Inc. (NASDAQ: NMRA). This action is on behalf of individuals and entities that acquired common stock during the company’s initial public offering (IPO) on September 15, 2023. Neumora is recognized as a clinical-stage biopharmaceutical firm focused on innovative therapies for neuropsychiatric conditions.

Allegations in the Class Action

The lawsuit raises significant allegations regarding Neumora’s purportedly misleading statements made in the offering documents. According to the complaint, the documents failed to provide crucial details about the company’s leading candidate, Navacaprant, intended to treat major depressive disorder (MDD).

Key Points Raised Include:
1. To pursue a Phase Three clinical program, Neumora was allegedly forced to change the original inclusion criteria of BlackThorn's Phase Two trial to accommodate patients with moderate to severe MDD. This alteration was essential to demonstrate any statistical advantage that Navacaprant could offer for treating MDD as a standalone therapy.
2. Furthermore, adjustments were made to the statistical analysis plan of the Phase Two trials. These modifications were aimed at focusing on the specific patient demographic suffering from moderate to severe MDD.
3. The plaintiffs argue that the Phase Two studies lacked sufficient data, particularly concerning the demographic representation of the participants (the ratio of male to female), leading to an inability to accurately forecast outcomes for the subsequent KOASTAL-1 study.

On January 2, 2025, numerous undisclosed negative facts came to light when Neumora disclosed the results from its KOASTAL-1 study. This disclosure revealed that the study did not show statistically significant improvement in its primary outcome measures when treated with Navacaprant for moderate to severe depression. The results highlighted that the treatment did not yield meaningful changes in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at the six-week mark, nor in the secondary endpoint of the Snaith-Hamilton Pleasure Scale (SHAPS).

Financial Impact on Shareholders

Since the date of its IPO at $17 per share, Neumora’s stock has seen a considerable decline. As of February 5, 2025, the closing price was reported at merely $1.91, translating to an approximate loss of 88.7% from the original IPO price. This substantial drop indicates a critical financial fallout for early investors.

Next Steps for Investors

Shareholders who are interested in participating in the class action are urged to file their lead plaintiff papers by April 7, 2025. The lead plaintiff serves an essential role in representing the class and steering the litigation process. Notably, individuals are not required to take any action to still qualify for potential recovery. Those who opt to remain passive participants may be counted as absent class members.

Robbins LLP operates on a contingency fee basis, meaning investors do not incur any upfront fees or expenses.

About Robbins LLP

Robbins LLP is a prominent firm specializing in issues related to shareholder rights, dedicated since 2002 to helping investors retrieve losses, enhance corporate governance, and demand accountability from company executives for any misconduct.

For updates regarding potential settlement status in the Neumora Therapeutics class action, or to be alerted about future incidences of corporate misconduct, investors are encouraged to register for the Stock Watch service provided by Robbins LLP.

For more information or to discuss eligibility, shareholders can contact attorney Aaron Dumas, Jr. via phone at (800) 350-6003, or visit the Robbins LLP website.